Ever since Ehrlich and colleagues described the existence of the blood-brain barrier (BBB), it has been appreciated that the BBB presents a real challenge in drug development for numerous brain disorders l. This is especially true for biologies such as antibodies that are large in size and unable to cross the BBB efficiently. As biologies become increasingly important as human therapeutics 2 novel systems that promote their access to the brain are desperately needed. One of the most promising approaches to delivering biologies efficiently into the brain is based on the Trojan horse principle 3.
展开▼
